Cargando…

NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. Nucleosome assembly protein 1-like 5 (NAP1L5) is a protein-coding gene that encodes a protein similar to nucleosome assembly protein 1 (NAP1). It is a histone chaperone that plays an important role in gene transcr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Rui, Ge, Yuzhen, Gong, Yongjun, Li, Bo, Xiao, Benli, Zuo, Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740361/ https://www.ncbi.nlm.nih.gov/pubmed/36374212 http://dx.doi.org/10.18632/aging.204377

Ejemplares similares

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
por: Gohr, Katharina, et al.
Publicado: (2017)

Puerarin 6″‐O‐xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR
por: Li, Long, et al.
Publicado: (2020)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Huang, Jie, et al.
Publicado: (2023)

HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway
por: Chen, Jianxu, et al.
Publicado: (2019)

CDCA2 Promotes HCC Cells Development via AKT–mTOR Pathway
por: Li, Kai, et al.
Publicado: (2022)

Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways
por: Li, Yun, et al.
Publicado: (2022)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

Retracted: Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Markers, Disease
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma
por: Wu, Ning, et al.
Publicado: (2018)

Deoxyshikonin isolated from Arnebia euchroma inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway
por: Zhu, Yuzhen, et al.
Publicado: (2019)

Resistin targets TAZ to promote osteogenic differentiation through PI3K/AKT/mTOR pathway
por: Shang, JingJing, et al.
Publicado: (2023)

Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish
por: Bu, Haisong, et al.
Publicado: (2021)

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma
por: Westhoff, Mike-Andrew, et al.
Publicado: (2013)

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
por: Babichev, Yael, et al.
Publicado: (2016)

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015)

The PI3K-AKT-mTOR pathway activates recovery from general anesthesia
por: Zhang, Yun-Hui, et al.
Publicado: (2016)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ab7akbhhnebpr6uet5dsdj33kp